Literature DB >> 3565791

Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects.

J X Mazoit, P Sandouk, P Zetlaoui, J M Scherrmann.   

Abstract

Published reports of morphine pharmacokinetics differ, perhaps because of analytical discrepancies and different study protocols. A highly specific radioimmunoassay (N-carboxymethylnormorphine RIA) was used to measure unchanged morphine in plasma in six normal subjects and in eight cirrhotic patients with hypoalbuminemia, hyperbilirubinemia, and prolonged prothrombin time. All subjects received a single intravenous bolus of morphine hydrochloride (0.1 mg/kg). Peripheral blood samples were collected at frequent intervals from 2 min to 36 hr after injection. In cirrhotic patients as compared with normal subjects, terminal half-life of unchanged morphine was longer (201 +/- 39 vs 111 +/- 32 min (mean +/- SD), P less than 0.01) and total body clearance was slower (21 +/- 7.5 vs 33.5 +/- 8 ml X min-1 X kg-1, P less than 0.05). The apparent volume of distribution and the steady-state volume of distribution did not differ in the two groups. In conclusion, cirrhotic patients have a prolonged terminal half-life of unchanged morphine that is attributable to a decrease in total body clearance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3565791

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  22 in total

1.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

2.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

4.  The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.

Authors:  J Hasselström; S Eriksson; A Persson; A Rane; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

5.  Enhanced drug metabolism in young children with cystic fibrosis.

Authors:  A C Parker; P Pritchard; T Preston; R L Smyth; I Choonara
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

Review 6.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 8.  Role of supportive care for terminal stage hepatocellular carcinoma.

Authors:  Manoj Kumar; Dipanjan Panda
Journal:  J Clin Exp Hepatol       Date:  2014-03-31

Review 9.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 10.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.